During the past decade, Central Alabama Research conducted 25 clinical trials. In the 10-year time frame, 25 clinical trials started and 15 clinical trials were completed, i.e. on average, 60% percent of trials that started reached the finish line to date. In the past 5 years, 13 clinical trials started and 9 clinical trials were completed. i.e. 69.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Central Alabama Research" #1 sponsor was "Pfizer" with 5 trials, followed by "Janssen Research & Development, LLC" with 2 trials sponsored, "Kowa Research Institute, Inc." with 2 trials sponsored, "NewAmsterdam Pharma" with 2 trials sponsored and "NovoCure GmbH" with 2 trials sponsored. Other sponsors include 12 different institutions and companies that sponsored additional 22 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Central Alabama Research" #1 collaborator was "Eli Lilly and Company" with 2 trials as a collaborator, "Medpace, Inc." with 1 trials as a collaborator, "Merck Sharp & Dohme LLC" with 1 trials as a collaborator, "PPD" with 1 trials as a collaborator and "The Cleveland Clinic" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Central Alabama Research" are "Hypertension" (3 trials), "Atherosclerotic Cardiovascular Disease" (2 trials), "Cardiovascular Disease" (2 trials), "Respiratory Syncytial Virus" (2 trials) and "Severe Hypertriglyceridemia" (2 trials). Many other conditions were trialed in "Central Alabama Research" in a lesser frequency.

Most popular intervention types in "Central Alabama Research" are "Drug" (25 trials), "Biological" (3 trials), "Device" (3 trials), "Other" (2 trials) and "Diagnostic Test" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (15 trials), "Fenofibrate" (2 trials), "K-877" (2 trials), "Metformin XR" (2 trials) and "NovoTTF-200T" (2 trials). Other intervention names were less common.

The vast majority of trials in "Central Alabama Research" are 30 trials for "All" genders.

Currently, there are NaN active trials in "Central Alabama Research". undefined are not yet recruiting, 5 are recruiting, 4 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 14 completed trials in Central Alabama Research, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in Central Alabama Research, 0 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 17 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 3 trials, and there were also 1 trials that are defined as “Not Applicable".